Reuters logo
BRIEF-Bavarian Nordic announces 6-mth follow-up data from phase 1 trial of MVA-BN RSV
February 23, 2017 / 3:33 PM / 8 months ago

BRIEF-Bavarian Nordic announces 6-mth follow-up data from phase 1 trial of MVA-BN RSV

Feb 23 (Reuters) - Bavarian Nordic A/S:

* Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

* Says antibody levels maintained against multiple targets 6 months post vaccination

* Additional T cell data confirms broad activity against all 5 RSV targets included in the vaccine

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below